KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma

Histopathology
Mitra MehradSanja Dacic

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small-cell lung carcinoma (NSCLC) with aggressive behaviour. This study aimed to evaluate the prognostic clinicopathological and genetic characteristics of PSCs. Fifty-three cases of surgically treated PSCs were selected, 23 of which were subjected to mutation and copy number variation analysis using the 50-gene Ion AmpliSeq Cancer Panel. The majority of the patients were male (32 of 53, 60.3%) and smokers (51 of 53, 96.2%). Overall, 25 (47.1%) patients died within 2-105 months (mean = 22.7 months, median = 15 months) after diagnosis, and 28 were alive 3-141 months (mean = 38.7 months, median = 21.5 months) after diagnosis. Five-year overall survival was 12.5%. KRAS codon 12/13 mutation in adenocarcinomas (P = 0.01), age more than 70 years (P = 0.008) and tumour size ≥4.0 cm (P = 0.02) were associated strongly with worse outcome. TP53 (17 of 23, 74.0%) and KRAS codon 12 of 13 mutations (10 of 23, 43.4%) were the most common genetic alterations. Potentially actionable variants were identified including ATM (four of 23, 17.3%), MET, FBXW7 and EGFR (two of 23, 8.7%), AKT1, KIT, PDGFRA, HRAS, JAK3 and SMAD4 (one of 23, 4.3%). MET exon 14 skipping and missense muta...Continue Reading

References

Aug 30, 1990·The New England Journal of Medicine·R J SlebosW J Mooi
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ming-Sound TsaoFrances A Shepherd
Jan 22, 2009·Japanese Journal of Clinical Oncology·Atsuhito UshikiJun Nakayama
Aug 15, 2009·International Journal of Cancer. Journal International Du Cancer·Antoine ItalianoFlorence Pedeutour
Apr 1, 2010·Nature Methods·Ivan A AdzhubeiShamil R Sunyaev
Jul 6, 2010·Nucleic Acids Research·Kai WangHakon Hakonarson
Apr 21, 2012·Briefings in Bioinformatics·Helga ThorvaldsdóttirJill P Mesirov
Feb 12, 2014·American Journal of Clinical Pathology·Zaibo LiSara E Monaco
Jul 6, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Thibault VieiraMarie Wislez
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Nov 22, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Helena A YuGregory J Riely
Feb 24, 2015·Bioinformatics·Adrian TanHyun Min Kang
May 15, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V FalletM Wislez
Jul 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xuewen LiuAlain C Borczuk
Aug 21, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·William D TravisAndrew G Nicholson
Dec 29, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Carrie LeeJared Weiss
Jan 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark M AwadLynette M Sholl
Apr 16, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Frank SchneiderSanja Dacic
Apr 23, 2016·PLoS Computational Biology·Eric TalevichBoris C Bastian
Apr 24, 2016·Clinical Lung Cancer·Mony UngJulien Mazières
May 10, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Filippo LococoAlessia Ciarrocchi
May 14, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Simone Bsp TerraJennifer M Boland
Jun 28, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Alexa B SchrockSai-Hong Ignatius Ou
Mar 21, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Alexa B SchrockJane J Liu

❮ Previous
Next ❯

Citations

Sep 15, 2020·Therapeutic Advances in Medical Oncology·Xin LiJun Chen
Mar 9, 2021·The Journal of Thoracic and Cardiovascular Surgery·Hussein M AbdallahOlugbenga T Okusanya
Dec 10, 2021·Future Oncology·Yue ZhengYu Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.